Editorial Material
Pharmacology & Pharmacy
B. Gorovits, A. Hays, D. Jani, C. Jones, C. King, A. Lundequist, J. Mora, M. Partridge, D. Pathania, S. S. Ramaswamy, D. Rutwij, H. Shen, G. Starling
Summary: EURL ECVAM recommends discontinuing the use of animals for the development of antibodies, emphasizing that EU countries should adhere to Directive 2010/63/EU and not authorize animal immunization without legitimate scientific justification. AAPS acknowledges progress in reducing animal use in drug discovery but suggests more data and discussion within the scientific community are needed before implementing non-animal derived antibodies.
Article
Chemistry, Multidisciplinary
Angelina S. Bortoletto, W. Vallen Graham, Gabriella Trout, Alessandra Bonito-Oliva, Manija A. Kazmi, Jing Gong, Emily Weyburne, Brandy L. Houser, Thomas P. Sakmar, Ronald J. Parchem
Summary: Translation mentioned that one of the main pathological features of type 2 diabetes is the toxic accumulation of human islet amyloid polypeptide (hIAPP) aggregates. Current therapies fail to address hIAPP aggregation, while novel mAbs can serve as a diagnostic screening tool for early detection of T2D and protect beta cell function by targeting one of the underlying mechanisms of the disease.
Article
Engineering, Biomedical
Sonia Vicente-Ruiz, Ana Arminan, Katia Maso, Elena Gallon, Oleksandr Zagorodko, Julie Movellan, Fernanda Rodriguez-Otormin, Maike Baues, Jan-Niklas May, Federica De Lorenzi, Twan Lammers, Maria J. Vicent
Summary: Modifying biological agents with polymers such as PEG has clinical benefits, but PEGylated derivatives have toxicity issues, which leads to the search for alternatives. Conjugating PGA to AVE1642 alters its bio-nano interface and anti-tumor activity, inhibiting IGF-1R internalization and altering cell trafficking. PGA conjugation enhances AVE1642's anti-tumor activity and inhibits PI3K and MAPK signaling more effectively than AVE1642 alone.
Review
Oncology
Jakub Radocha, Niels W. C. J. van de Donk, Katja Weisel
Summary: Monoclonal antibodies have significantly advanced the treatment of multiple myeloma, with anti-CD38 antibodies and SLAM-F7 antibodies showing significant improvements in patient outcomes. Novel monoclonal antibody drug conjugates have also provided hope for refractory multiple myeloma patients.
Article
Chemistry, Analytical
Xiaoxi Zhang, Teresa Kwok, Mike Zhou, Min Du, Victor Li, Tao Bo, Tiemin Huang, Tong Chen
Summary: Since the development of the first commercial imaged capillary isoelectric focusing (icIEF) instrument twenty years ago, this technology has become the gold standard for quality and manufacturing process control in the bio-pharmaceutical industry. This study presents a robust and flexible icIEF-MS platform that allows for rapid icIEF separation and high-resolution MS identification of protein charged variants simultaneously.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
(2023)
Article
Biochemistry & Molecular Biology
Chiara Testa, Anna Maria Papini, Reinhard Zeidler, Daniela Vullo, Fabrizio Carta, Claudiu T. Supuran, Paolo Rovero
Summary: This study reports the first Antibody-Drug-Conjugates (ADCs) containing human Carbonic Anhydrase (CA) directed Monoclonal Antibodies (MAbs) linked to low molecular weight inhibitors. The results show potent inhibition of tumor-associated CA enzymes and off-target human CA isoforms. These findings support the development of a novel class of ADCs for the treatment of chronic diseases such as cancer and inflammation.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
(2022)
Review
Immunology
Olivier Tshiani Mbaya, Philippe Mukumbayi, Sabue Mulangu
Summary: The unprecedented West Africa Ebola outbreak from 2013-2016 accelerated the development of medical countermeasures against Ebola virus disease. In the recent second-largest Ebola outbreak in the Democratic Republic of the Congo, two IPs, REGN-EB3 and mAb114, showed efficacy compared to the control arm ZMapp in an RCT. The FDA approved both medications, marking a significant advancement in EVD therapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Biotechnology & Applied Microbiology
Andreas H. Laustsen, Victor Greiff, Aneesh Karatt-Vellatt, Serge Muyldermans, Timothy P. Jenkins
Summary: The debate on the benefits and drawbacks of antibody discovery through animal immunization versus in vitro selection from nonanimal-derived recombinant repertoires has persisted for years. While some argue that using recombinant display libraries can reduce animal consumption, the number of animals sacrificed during preclinical studies far exceeds those used in immunization campaigns. Therefore, improving quality control before in vivo studies will have a larger impact on animal consumption. Both animal immunization and recombinant repertoires offer unique advantages for discovering fit-for-purpose antibodies. Additionally, machine learning is expected to play a significant role in refining current antibody discovery practices.
TRENDS IN BIOTECHNOLOGY
(2021)
Article
Microbiology
Marina E. Kirkland, Stephanie Patfield, Anna C. Hughes, Bradley Hernlem, Xiaohua He
Summary: Shiga toxin-producing Escherichia coli infections are difficult to treat. However, a potentially therapeutic humanized mouse monoclonal antibody (Hu-mAb 2-5) targeting the most common Shiga toxin subtype has shown high neutralizing efficacy in vivo, protecting mice from mortality and HUS-related tissue damage.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Immunology
Brian M. Petersen, Sophia A. Ulmer, Emily R. Rhodes, Matias F. Gutierrez-Gonzalez, Brandon J. Dekosky, Kayla G. Sprenger, Timothy A. Whitehead
Summary: Monoclonal antibodies are key therapeutics for cancer, inflammation, and infectious diseases. Natural human antibody repertoire-based scoring matrices can accurately predict mutations in therapeutic antibodies. High frequency mutations in natural human antibody repertoires have the potential to improve existing therapeutic antibodies and reduce immunogenicity.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Hematology
Joshua Richter, Santiago Thibaud
Summary: Over the past decade, there has been a significant improvement in the outcomes of patients with multiple myeloma, largely due to the introduction of new therapies and the ability to combine medications without causing harmful toxicity. The use of diverse mechanisms in drug combinations, particularly with the incorporation of antibody-based therapy, has enhanced treatment efficacy in myeloma.
Review
Biochemistry & Molecular Biology
Igor Jaszczyszyn, Weronika Bielska, Tomasz Gawlowski, Pawel Dudzic, Tadeusz Satlawa, Jaroslaw Konczak, Wiktoria Wilman, Bartosz Janusz, Sonia Wrobel, Dawid Chomicz, Jacob D. Galson, Jinwoo Leem, Sebastian Kelm, Konrad Krawczyk
Summary: AlphaFold2 has made a significant advancement in protein structure prediction, especially in antibody structure prediction, which has greatly impacted drug discovery. However, antibody-specific applications require tailored adjustments, leading to the development of several deep learning antibody structure predictors. In this review, we discuss the recent progress in antibody structure prediction and its contribution to biologics discovery.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2023)
Editorial Material
Nanoscience & Nanotechnology
Martin Listek, Anja Ho''now, Manfred Gossen, Katja Hanack
Summary: The original paper presented an approach to select specific hybridoma cells from a polyclonal hybridoma pool by utilizing a cell surface anchor to capture secreted antibodies. The antigen-specific detection was conducted using streptavidin-labeled antigen and a PE-labeled anti-F(ab')2 antibody. This comment provides a clearer description of the selection system originally published by Listek et al. in 2020, along with additional information on the importance of controls and recent adaptations made by the authors' lab.
ACS APPLIED MATERIALS & INTERFACES
(2023)
Review
Pharmacology & Pharmacy
Giulia Pander, Philipp Uhl, Nikos Kuehl, Uwe Haberkorn, Jan Anderl, Walter Mier
Summary: Antibody-drug conjugates (ADCs) are a new type of drug widely used in targeted cancer treatment. By guiding highly toxic compounds to target cells, ADCs can reduce damage to healthy cells. Recent research has focused on stimulating immune responses to induce immunogenic cell death and influencing the tumor microenvironment to enhance treatment effects.
DRUG DISCOVERY TODAY
(2022)
Review
Pharmacology & Pharmacy
Long-Can Mei, Yin Jin, Zheng Wang, Ge-Fei Hao, Guang-Fu Yang
Summary: This review introduces resource repositories for the development of COVID-19 therapeutics, covering data from genome and proteome to antiviral drugs, vaccines, and monoclonal antibodies. The authors briefly describe how these data advance research for therapies and discuss opportunities and challenges to prevent the pandemic from developing further.
DRUG DISCOVERY TODAY
(2021)